Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vamorolone
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Santhera Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Santhera Launches AGAMREE® Early Access in China by its Partner Sperogenix
Details : Agamree (vamorolone) is a novel drug with a mode of action based on binding to the same receptor as glucocorticoids. It is approved for the treatment of duchenne muscular dystrophy.
Product Name : Agamree
Product Type : Steroid
Upfront Cash : Inapplicable
October 06, 2024
Lead Product(s) : Vamorolone
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Santhera Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
